Tdark LURAP1 Leucine rich adaptor protein 1

Protein Summary

Description

Acts as an activator of the canonical NF-kappa-B pathway and drive the production of proinflammatory cytokines. Promotes the antigen (Ag)-presenting and priming function of dendritic cells via the canonical NF-kappa-B pathway (PubMed:21048106). In concert with MYO18A and CDC42BPA/CDC42BPB, is involved in modulating lamellar actomyosin retrograde flow that is crucial to cell protrusion and migration. Activates CDC42BPA/CDC42BPB and targets it to actomyosin through its interaction with MYO18A, leading to MYL9/MLC2 phosphorylation and MYH9/MYH10-dependent actomyosin assembly in the lamella (By similarity).

Uniprot Accession IDs

• Q96LR2

Gene Name

• LURAP1

Ensembl ID

• ENST00000371980
• ENSP00000361048
• ENSG00000171357

Symbol

• C1orf190
• LRAP35A
• LRP35A
• LRP35A
• LRAP35a
• C1orf190

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
tissue sample	0.61
cell line	0.48
microRNA	0.48
transcription factor	0.48
histone modification site profile	0.45

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 4.08   (req: < 5)

Gene RIFs: 2   (req: <= 3)

Antibodies: 62   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 4.08   (req: >= 5)

Gene RIFs: 2   (req: > 3)

Antibodies: 62   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 4

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0